| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Dihydrolycorine targets protein synthesis in eukaryotic cells as an inhibitor, blocking the peptide bond formation step. It also targets alpha 1-adrenoceptors as a blocker. The compound exhibits antihypertensive and neuroprotective activities. It inhibits methoxamine-induced contraction of isolated rabbit aortic rings and rat anococcygeus muscle with pA2 values of 5.93 and 6.35, respectively. Dihydrolycorine reduces infarct size.
|
|---|---|
| ln Vitro |
In vitro, Dihydrolycorine inhibits protein synthesis in eukaryotic cells by inhibiting the peptide bond formation step. It blocks alpha 1-adrenoceptors. The compound inhibits methoxamine-induced contraction of isolated rabbit aortic rings and rat anococcygeus muscle with pA2 values of 5.93 and 6.35, respectively. It exhibits antihypertensive and neuroprotective activities. Dihydrolycorine reduces infarct size.
|
| ln Vivo |
Dihydrolycorine, with pA2 values of 5.93 and 6.35, respectively, reduces methoxamine-induced contraction of isolated rabbit aortic rings and rat coccygeus muscles [2].
In vivo, Dihydrolycorine exhibits antihypertensive and neuroprotective activities. It reduces infarct size. The compound blocks alpha 1-adrenoceptors, contributing to its hypotensive effects. It is a derivative of the alkaloid lycorine with potential therapeutic applications in cardiovascular and neurological disorders. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic properties. |
| Enzyme Assay |
In vitro enzyme assays for Dihydrolycorine involve measuring protein synthesis inhibition in eukaryotic cells. Protein synthesis is assessed by measuring incorporation of radiolabeled amino acids into proteins. The compound is added at varying concentrations, and IC50 values are calculated from dose-response curves. Alpha 1-adrenoceptor antagonism is assessed by measuring inhibition of methoxamine-induced contraction in isolated tissue preparations, with pA2 values calculated from dose-response curves.
|
| Cell Assay |
In vitro cell-based assays for Dihydrolycorine are conducted in eukaryotic cell lines such as ascites cells and HeLa cells. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. Protein synthesis is assessed by measuring radiolabeled amino acid incorporation. Cell viability is assessed by standard assays. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Dihydrolycorine in vivo studies are conducted in animal models of hypertension and neuroprotection. Animals are treated with Dihydrolycorine via oral administration or injection. Blood pressure is monitored for antihypertensive effects. For neuroprotection studies, animal models of ischemia or neurodegeneration are used and infarct size is measured. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis at study endpoints.
|
| ADME/Pharmacokinetics |
Dihydrolycorine (MW 287.31 g/mol, C16H17NO4) is an alkaloid derived from Lycoris radiata. It is a derivative of lycorine. The compound is soluble in DMSO and other organic solvents. It is stable under recommended storage conditions. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies. Dihydrolycorine is used in cardiovascular and neuroprotection research.
|
| Toxicity/Toxicokinetics |
Dihydrolycorine is generally well-tolerated in preclinical studies. The compound is a natural alkaloid with established safety profiles. Its antihypertensive and neuroprotective activities have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Dihydrolycorine is an alkaloid. It has been reported to exist in sea neem, snowdrop, and lycoris, and relevant data are available for reference.
Dihydrolycorine is an alkaloid from Lycoris radiata and a protein synthesis inhibitor that blocks the peptide bond formation step. It is an alpha 1-adrenoceptor blocker with antihypertensive and neuroprotective activities. The compound inhibits methoxamine-induced contraction (pA2 = 5.93 and 6.35) and reduces infarct size. Its molecular formula is C16H17NO4 with a molecular weight of 287.31 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C16H19NO4
|
|---|---|
| Molecular Weight |
289.3264
|
| Exact Mass |
289.131
|
| Elemental Analysis |
C, 66.42; H, 6.62; N, 4.84; O, 22.12
|
| CAS # |
6271-21-2
|
| PubChem CID |
11876135
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
460.5±45.0 °C at 760 mmHg
|
| Melting Point |
247℃
|
| Flash Point |
232.3±28.7 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.701
|
| LogP |
0.85
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
21
|
| Complexity |
433
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O([H])[C@]1([H])[C@]([H])(C([H])([H])[C@@]2([H])C([H])([H])C([H])([H])N3C([H])([H])C4=C([H])C5=C(C([H])=C4[C@@]1([H])[C@]32[H])OC([H])([H])O5)O[H]
|
| InChi Key |
VJILFEGOWCJNIK-MGRBZGILSA-N
|
| InChi Code |
InChI=1S/C16H19NO4/c18-11-3-8-1-2-17-6-9-4-12-13(21-7-20-12)5-10(9)14(15(8)17)16(11)19/h4-5,8,11,14-16,18-19H,1-3,6-7H2/t8-,11+,14+,15-,16-/m1/s1
|
| Chemical Name |
(1S,15R,17S,18S,19R)-5,7-dioxa-12-azapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-2,4(8),9-triene-17,18-diol
|
| Synonyms |
Dihydrolycorine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~12.5 mg/mL (~43.20 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (4.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (4.32 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4563 mL | 17.2813 mL | 34.5626 mL | |
| 5 mM | 0.6913 mL | 3.4563 mL | 6.9125 mL | |
| 10 mM | 0.3456 mL | 1.7281 mL | 3.4563 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
